Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol/Dexborneol (Y-6) for Microcirculation Dysfunction in AIS
NCT05836766Phase 2Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cilostazol and dexborneol in ischemic stroke (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Proportion of mRS score recovered to 0~1 score at 90 days. Status: unknown.
02
Drugs
cilostazoldexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05836766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836766.